Totient has expertise in identifying human antibodies in patients with different immune responses; it has reconstructed more than 4,500 antibodies from over 50,000 patients, AbSci said. The company hopes to develop natural human antibodies and target antigens using this expertise and to establish training sets for its Denovium Engine deep-learning model.

AbSci secures $125M in financing
Synthetic biology company AbSci has secured $125 million in financing that it plans to use to further develop its artificial intelligence platform...

AbSci acquires Denovium for protein AI platform
AbSci, a synthetic biology company, has acquired Denovium, an artificial intelligence (AI) deep-learning company.

Totient advances anti-SARS-CoV-2 antibodies with funding, partnerships
Ginkgo Bioworks and artificial intelligence drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus...